Markets:

Overview

News

Currencies

International

Treasuries

MorphoSys AG - American Depositary Shares (NQ:MOR)

18.96 UNCHANGED

Last Price Updated: 4:00 PM EDT, Aug 2, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about MorphoSys AG - American Depositary Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

MorphoSys to Present Data on Tafasitamab (Monjuvi(R)) at the 2021 ASCO Annual Meeting

May 19, 2021

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / May 19, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new data from the tafasitamab (Monjuvi(R)) development program will be presented at the...

From MorphoSys AG

Via AccessWire

The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO ↗

May 18, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 17) Alexion Pharmaceuticals, Inc...

Via Benzinga

Earnings Scheduled For May 5, 2021 ↗

May 05, 2021

Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter. • EyePoint Pharmaceuticals (NASDAQ:EYPT...

Via Benzinga

The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron ↗

May 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ...

Via Benzinga

MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma

May 11, 2021

PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / May 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that the first patient has been dosed in the pivotal...

From MorphoSys AG

Via AccessWire

Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma

May 11, 2021

From Incyte

Via Business Wire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

May 10, 2021

Gainers Conformis (NASDAQ:CFMS) stock moved upwards by 29.53% to $1.09 during Monday's pre-market session. The company's market cap stands at $198.8 million. As...

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

May 11, 2021

Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was Snowflake (NYSE:SNOW...

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

May 10, 2021

Monday morning saw 78 companies set new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was Rocket Companies (NYSE:RKT)....

Via Benzinga

MorphoSys AG (MOR) Q1 2021 Earnings Call Transcript ↗

May 06, 2021

MOR earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom ↗

May 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

MorphoSys AG Reports First Quarter 2021 Results

May 05, 2021

- MonjuviU.S. net product sales of € 12.9 million (US$ 15.5 million) - Tremfya royalties of € 11.6 million - Reaffirming group revenue guidance of € 150 to € 200 million - Conference call and webcast...

From MorphoSys AG

Via AccessWire

Stocks That Hit 52-Week Lows On Wednesday ↗

May 05, 2021

Wednesday morning, 15 companies reached new 52-week lows. Interesting Facts: The largest company in terms of market cap to set a new 52-week low was Vistra (NYSE:...

Via Benzinga

DGAP-News: Invitation to MorphoSys' First Quarter Results Conference Call on May 6, 2021

April 28, 2021

Conference Call Alert Invitation to MorphoSys' First Quarter Results Conference Call on May 6, 2021 MUNICH, GERMANY / ACCESSWIRE / April 28, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ: MOR), a...

From MorphoSys AG

Via AccessWire

MorphoSys and Incyte Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma

April 19, 2021

PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / April 19, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced the first...

From MorphoSys AG

Via AccessWire

The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex ↗

April 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Alexion Pharmaceuticals,...

Via Benzinga

Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma

April 19, 2021

From Incyte and MorphoSys AG

Via Business Wire

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.